comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 05:33:27 - browse：59377

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Woodcock on FDA’s accelerated approval and her next chapter

entertainment

WSS

Syphilis numbers in the United States reach record heights

Merck, Johnson & Johnson CEOs will testify on high drug prices

Investment in vaccine development is lagging, report finds

Humana’s losses in Medicare Advantage tank its stock

Cognito secures funding to test medical device for Alzheimer's

FDA drug safety: Singulair case shows systemic surveillance flaws

Wikipedia

comprehensive

focus

Bright Health sells Medicare Advantage business to Molina

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Novavax promises a turnaround & Lilly roils the obesity market

Merck, Johnson & Johnson CEOs will testify on high drug prices

In Memoriam: Notable people who died in 2023

Merck CEO won’t testify in Senate, citing no expertise in drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Anesthesiologist group: stop taking Ozempic before surgery

Commercial surrogacy can be ethical, despite pope’s claims

Wikipedia

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Covid misinformation case heads to Supreme Court

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Time to name cancers by genetics, not organ of origin, expert says

New clues to why women have higher risk of autoimmune disorders

Investment in vaccine development is lagging, report finds

entertainment

leisure time

hotspot

entertainment